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Abstract: Information about long-term safety issues from use of orphan drugs in treatment of 
hereditary angioedema (HAE) is limited and must be studied further. As clinical trials in patients 
with rare diseases are limited, prescribers and patients have to rely on spontaneous adverse drug 
reaction (ADR) reports for obtaining major information about the serious, rarely occurring, and 
unknown ADRs. In this study, we aimed to characterize ADRs reported for HAE medications 
in Europe from 2007 to 2013. ADR reports submitted for C1-inibitors and bradykinin receptor 
antagonists to the European ADR database, EudraVigilance (EV), were included in this study. 
The ADR reports were categorized with respect to age and sex of the patients, category of the 
reporter, type and seriousness of the reported ADRs, and medications. The unit of analysis was 
one adverse event (AE). Totally, 187 AEs were located in EV, and of these, 138 AEs were reported 
for Cinryze® (C1-inhibitor) (73% of the total) and 49 AEs for Firazyr® (icatibant) (26% of the 
total AEs). Approximately 60% of all AEs were serious, including three fatal cases. Less than 
5% of AEs were reported in children. In total, 62% of AEs were reported for women and 38% 
for men. For both Cinryze® and Firazyr®, the majority of reported AEs were of the type “general 
disorders and administration site conditions”. For Cinryze®, a large number of AEs of the type 
“HAE” and “drug ineffective” was reported, but only few of these were serious. For Firazyr®, 
several nonserious reports on injection site reactions were reported. In conclusion, this study 
showed that in EV, several ADR reports from use of HAE medications were identified, and a 
large number of these were serious, including fatal cases.
Keywords: orphan drugs, hereditary angioedema, adverse drug reactions, adverse events, 
C1-inhibitor, Cinryze®, icatibant, Firazyr®, EudraVigilance
Introduction
Hereditary angioedema (HAE) is an autosomal dominant and rare disease which is 
caused by either a diminished level (HAE type 1) or dysfunction (HAE type 2) of 
complement C1-inhibitor.1–3 Complement C1-inhibitor deficiency causes an uncontrolled 
activation of the contact system with excessive bradykinin formation as the main out-
come.1–3 Symptoms of HAE are recurrent angioedema attacks without urticarial signs, 
typically characterized by swelling of the skin and/or mucosa. Angioedema episodes 
most frequently affect the extremities, abdomen, head/neck area, and the upper respira-
tory airways.1–3 HAE patients do not respond to traditional angioedema treatments, for 
example, antihistamines, glucocorticoids, and epinephrine, and for many years, HAE 
patients have been treated off-label with androgens and/or tranexamic acid. Hence, the 
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need for development of more effective and specific HAE 
treatments has been prevailing for both patients and health 
care professionals.4–6 Traditionally, the pharmaceutical indus-
try did not find it profitable to develop medicines for rare 
diseases, but with the worldwide implementation of national 
Orphan Diseases Acts, it has became more economically 
profitable to develop specific medications for treatment of 
HAE, the so-called orphan drugs.7,8 In the European Union 
(EU), a rare disease is defined as any disease occurring in 
less than 5 in 10,000 people, and consequently, orphan drugs 
are being licensed under favorable conditions with respect to 
demonstration of efficacy and safety.8 The EU Orphan Disease 
Act has led to the development of several new HAE-specific 
medical treatments, for example, C1-inhibitors,9–11 bradyki-
nin receptor antagonists (icatibant),12,13 and the recombinant 
plasma kallikrein inhibitor ecallantide (Kalbitor®; Dyax 
Corp.  Burlington, Vermont, USA).14–16 Lack of sufficient 
knowledge of long-term safety aspects from use of orphan 
drugs in treatment of HAE patients makes spontaneous ADR 
reporting systems an important source of information about 
medicine safety.17 As premarketing clinical trials within the 
area of rare diseases are scarce, clinicians and health authori-
ties have to rely on spontaneous reports as the major source 
of new information on ADRs, particularly data on serious 
and rarely occurring ADRs.17 Since 2012, researchers have 
been allowed to access the EU ADR database, EudraVigilance 
(EV), and this has opened for cross-national analysis based 
on a standardized reporting format.18 By February 2016, no 
studies have systematically analyzed postmarketing safety 
data reported for orphan drugs licensed for treatment of 
HAE and submitted to national ADR databases in Europe.19 
The aim of this study was to characterize the adverse events 
(AEs) reported for orphan drugs licensed for treatment of 
HAE submitted to the EV database from 2007 to 2013.
Materials and methods
study design
We retrospectively reviewed ADR reports submitted to the EV 
database for orphan drugs licensed for treatment of HAE in 
Europe. The reported AEs were analyzed with respect to their 
type and seriousness, age and sex of the patient, suspected 
medicines, and type of the reporter. The unit of analysis was 
one ADR. The age groups of the patients were categorized 
into two: children (0–17 year olds) and adults (18 year 
olds). AEs reported for HAE medications licensed through 
the central licensing procedure in the EU by the European 
Medicines Agency (EMA) were included in this study. The 
included HAE medications were  Berinert® (CLS Behring, 
Danderyd, Sweden) Cinryze® (Shire, Danderyd, Sweden), and 
 Ruconest® (Shire,  Danderyd,  Sweden) (C1-inhibitors – ATC 
code B06AC01) and Firazyr® (Shire, Danderyd, Sweden) 
(icatibant) (bradykinin receptor antagonist – ATC code 
B06AC02). Table 1 displays the characteristics of the included 
HAE medications, their approved indications and age groups, 
time of licensing in the EU, name of the marketing authoriza-
tion holder, and occurrence and type of reported adverse drug 
reactions listed in the latest version of the official product 
information. Information about the orphan drugs was retrieved 
through the website of the EMA. The C1-inhibitor Berinert®, 
which is also licensed for acute and prophylactic treatment of 
HAE, was excluded from this study. Berinert® is not centrally 
authorized in the EU, and therefore, we could not get access 
to the ADR reports reported for Berinert® through EMA.
Material
The EV database contains information about all suspected 
spontaneous ADR reports and the ADRs reported in clinical 
trials and postmarketing for all medicinal products authorized 
in the EU.20 ADR data should be transmitted electronically 
to the database in accordance with the International council 
on harmonisation of technical requirements for registra-
tion of Pharmaceuticals for human use (ICH E2B) (R2) 
standard.21 The EV database is not publicly accessible, and 
authorization for data access was given by the EMA.22 ADR 
information was provided for this study in anonymous form 
with encrypted personal identification.23 Data extraction 
and data analyses of the raw material were comprehensive 
and time consuming. ADR information was extracted from 
the EV database with respect to the type of reporter and the 
criteria of seriousness and medications for which the AEs 
were reported. Criteria of seriousness were evaluated and 
made by the reporters and the evaluations were confirmed 
by the national regulatory agencies before forwarding the 
ADR data to the EV database. The reported AEs were coded 
according to their type and seriousness using the Council for 
International Organizations of Medical Sciences criteria by 
the academic staff in the national regulatory agencies.24 ADR 
data were extracted from the EV database in Microsoft Excel 
files using the following criteria: patient’s sex and age, medi-
cines (active substance), adverse drug reaction, and severity.22 
The material comprised all ADR reports submitted to the 
EV database from 2007 to 2013. Data were extracted from 
the EV database and delivered to us as several large Excel 
files. In STATA® statistical software package (StataCorp LP, 
College Station, TX, USA), the Excel files were merged into 
one major file and the ADR reports were searched for dupli-
cates. Data analysis including coding of ADR reports was 
conducted in an Access database. Each ADR report may refer 
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to one or more suspected ADR(s) as well as to one or more 
medicinal products. In this study, we only included the AEs 
reported for medications, which were listed as suspect drug 
by the reporter, meaning that a causal relationship between 
the reported ADR and the drug was expected.
Classification of AEs by type and 
seriousness
The different types of reported AEs were classified according 
to the Medical Dictionary for Regulatory Activities System 
Organ Class (SOC).24 Serious AEs were defined as: fatal, 
Table 1 characteristics of orphan drugs licensed for treatment of hereditary angioedema in europe and information about adverse 
drug reactions (frequency and type) available in the official product information
Medications 
(alphabetical  
order)
Indication  
for use
Population Year of EU 
licensing
MAH Adverse drug reactions  
(frequency and type)
PI* version 
(month/year)
cinryze® 
(c1-esterase 
inhibitor human)
angioedema 
• acute 
• Prophylaxis
adolescents 
adults
2011 shire Orphan  
Therapies  
gmbh
Common: 
Rash 
Uncommon: 
abdominal pain 
arthralgia 
chest discomfort 
contact dermatitis 
cough 
Diarrhea 
Dizziness 
erythema 
headache 
Hot flush 
hyperglycemia 
injection site reactions 
Joint swelling 
Myalgia 
nausea 
Phlebitis 
Pyrexia 
Pruritus 
Venous burning/thrombosis 
Vomiting 
Not known: 
hypersensitivity reactions
12/2014
Firazyr®  
(icatibant)
angioedema 
• acute
adults 2008 shire Orphan  
Therapies  
gmbh
Very common (1/10): 
injection site reactions 
Transaminase increased 
Common (from 1/100 to ,1/10): 
Dizziness 
erythema 
headache 
nausea 
Pyrexia 
Pruritus 
Rash
03/2013
Ruconest®  
(conestat alfa)
angioedema 
• acute
adults 2010 swedish Orphan  
Biovitrum
Common (from 1/100 to ,1/10): 
headache 
Uncommon (from 1/1,000 to ,1/100): 
abdominal discomfort 
Diarrhea 
nausea 
Paresthesia 
swelling 
Throat irritation 
Urticaria 
Vertigo
10/2013
Note: *Pi: Product information available at the website of the european Medicines agency (http://www.ema.europa.eu/ema/).
Abbreviations: eU, european Union; Mah, Marketing authorization holder; Pi: product information.
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life-threatening, requiring hospitalization or prolongation 
of existing hospitalization, and resulting in persistent or 
significant disability/incapacity in the reporter’s assessment, 
in a congenital anomaly/birth defect, and other medically 
important conditions. All other AEs were classified as non-
serious.24 The scientific staffs working in the different national 
regulatory agencies made the seriousness evaluations, and 
these evaluations were forwarded to us together with the 
copies of the ADR reports.
ethical approval
According to Danish law, no ethical approval was required 
for this study.
Results
From 2007 to 2013, a total of 79 individual ADR reports con-
taining information about 187 AEs were found in EV for HAE 
medications licensed by the EMA (Table 2). For Cinryze®, 
a total of 60 ADR reports covering information about 138 AEs 
were reported, and for Firazyr®, the number was 19 reports 
and 49 AEs. No ADR reports were found for Ruconest® in 
the EV database. Health care professionals reported all ADR 
cases. In total, 62% of AEs were reported for women and 
38% for men. Approximately 5% of AEs were reported in 
0–17 year olds. Approximately 10% of ADR reports were 
found without information about patient age in EV.
aes by seriousness
In total, 60% (n=116) of all reported AEs (n=187) were 
classified as serious, and among these, three fatal cases were 
reported (Table 2). For Cinryze®, the share of serious AEs 
was 57% (n=80) and for Firazyr®, it was 70% (n=36). The 
characteristics of the three fatal cases are displayed in Table 3. 
For Cinryze®, one fatal case of sudden death presumably due 
to “basilar artery thrombosis” was reported in a 52-year-old 
male, and one fatal case due to the AEs “cytomegalovirus 
infection” and “cytomegalovirus test positive” in a male 
infant was also found in EV for Cinryze®. For Firazyr®, one 
fatal case of sudden death presumably due to “myocardial 
infarction” was reported in a 67-year-old male.
aes by type and seriousness
Table 4 shows the distribution of reported AEs by SOC, 
seriousness, and medicine. For Cinryze®, the largest shares 
of AEs were reported for the SOCs “general disorders and 
administration site conditions” (25% of the total AEs) and 
“skin and subcutaneous disorders” (25% of the total AEs). 
For Cinryze®, the majority of serious AEs were also found 
within the SOC “general disorders and administration site 
conditions” (60% of the reported AEs). For Firazyr®, majority 
of the reported AEs were of the type “general disorders and 
administration site conditions” (49% of the total AEs), and 
approximately 45% of these AEs were serious.
aes by medication
Table 5 displays the number of reported AEs by medicines 
and seriousness. For Cinryze®, the largest number of reported 
AEs was “HAE” (n=25) and “drug ineffective” (n=10); 
however, only a few of these ADR cases were serious. For 
Firazyr®, a large number of nonserious ADR reports on 
injection site reactions were found in EV. For both Cinryze® 
Table 2 Distribution of cases and adverse drug reactions (aes) for orphan drugs licensed for treatment of hae by medication, 
seriousness, age, and sex, found in the eudraVigilance database, 2007–2013
Medications  
(alphabetical order)
Sex Age (years):
Cases  
(n)
AEs  
(n)
Serious  
AEs (n)
Male  
(n)
Female  
(n)
NA 
(n)
,17  
(n)
18  
(n)
NA 
(n)
Berinert® na na na na na na na na na
cinryze® 60 138 80 53 85 1 9 116 13
Firazyr® 19 49 36 18 30 0 0 41 8
Ruconest® 0 0 0 0 0 0 0 0 0
Total 79 187 116 71 115 1 9 157 21
Abbreviations: ae, adverse effect; hae, hereditary angioedema; na, no information available in eudraVigilance.
Table 3 Fatal adverse drug reaction cases reported for cinryze® 
and Firazyr® in europe, 2007–2013
Case 
no
Year Medicine ATC 
group
Adverse drug 
reaction(s)
Age Sex
1 2008 cinryze® B06ac01 Basilar artery 
thrombosis
52 Male
Death
2 2010 cinryze® B06ac01 cytomegalovirus 
infection
,1 Male
cytomegalovirus  
test positive
Death
3 2012 Firazyr® B06ac02 Myocardial infarction 67 Male
Note: ATC, Anatomical therapeutic chemical classification system.
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and Firazyr®, only 10% of the reported AEs were already 
mentioned in the official product information.
Discussion
This is the first study conducted to analyze postmarketing 
ADR data reported for orphan drugs licensed for treatment 
of HAE in Europe and submitted to the EV ADR database. 
Only few ADR reports, all for the medications Cinryze® and 
Firazyr®, were found in EV, and a large number of these were 
serious. More than one half of AEs were reported for women, 
and physicians reported all the AEs. A large number of AEs 
reported for Cinryze® and Firazyr® were of the type “general 
disorders and administration site conditions”. The majority 
of AEs reported for both Cinryze® and Firazyr® were not 
mentioned in the official product information.17
Reported aes by type and seriousness
The majority of AEs reported for Cinryze® and Firazyr® 
were of the type “general disorders and administration site 
conditions”, for example, injection site reactions, and this 
ADR pattern was expected due to their route of administra-
tion parenteral. Additionally, for Cinryze®, a large number 
of AEs of the type “skin and subcutaneous disorders” 
Table 4 number of adverse drug reactions reported for hae 
medications distributed by system organ class, seriousness (in 
parentheses), and medicine, 2007–2013
System organ class  
(alphabetical order)
Cinryze® 
Total (n) 
(serious)
Firazyr® 
Total (n) 
(serious)
Blood and blood forming organs 8 (8) na
cardiac disorders 2 (2) 7 (7)
congenital, familial, and genetic disorders 4 (4) 1 (1)
gastrointestinal disorders 7 (7) 1 (1)
general disorders and administration site 
conditions
36 (25) 25 (12)
hepatobiliary disorders 3 (3) 2 (2)
immune system disorders 4 (4) 1 (1)
infections and infestations 2 (2) na
injury, poisoning, and procedural  
complications
6 (5) na
investigations 1 (1) 3 (3)
Metabolism and nutrition disorders 2 (1) na
Musculoskeletal and connective tissue  
disorders
8 (0) 3 (3)
nervous system disorders 3 (1) 1 (1)
Pregnancy, puerperium, and perinatal  
conditions
8 (9) na
skin and subcutaneous disorders 33 (6) 5 (5)
Vascular disorders 6 (2) na
Total 138 (80) 49 (36)
Abbreviations: hae, hereditary angioedema; na, no information available in 
eudraVigilance.
Table 5 number of reported adverse events by type (preferred 
term), seriousness (in parentheses), and medicine reported in 
europe from 2007 to 2013
Adverse drug 
reaction  
(alphabetical order)
Cinryze® 
Total (n) 
(serious)
AE listed  
in PI  
(yes/no)
Firazyr® 
Total (n) 
(serious)
AE listed 
in PI  
(yes/no)
abdominal pain 2 (2) Y 1 (1) n
abortion 4 (4) n – –
acidosis 1 (1) n – –
acute respiratory  
failure
1 (1) n – –
adverse event 1 (1) n 2 (2) –
anaphylactic shock 2 (2) n – n
angioedema 2 (0) n 1 (1) n
anomaly of external  
ear congenital
1 (1) n – n
arteriospasm coronary – – 2 (2) n
arthralgia 2 (0) Y 1 (1) n
asthenia 2 (0) n – n
Basilar artery 
thrombosis
1 (1) n – n
Blood pressure 
fluctuations
1 (1) n 2 (2) n
Bronchopneumonia 1 (1) n – n
c1-esterase inhibitor  
decreased
1 (1) n – n
chest pain – Y 3 (3) n
chills – n 1 (0) n
circulatory collapse 1 (1) n – –
coagulation factor iX  
level increased
1 (1) n – –
coagulation factor Viii 
level increased
1 (1) n – –
condition aggravated 3 (1) n – –
cytomegalovirus  
infection
1 (1) n – –
cytomegalovirus test 1 (1) n – –
Deep vein thrombosis 1 (1) Y – –
Death 2 (2) n – –
Dizziness 2 (2) Y 1 (1) Y
Drug abuse 2 (2) n – –
Drug ineffective 10 (10) n 2 (2) n
Drug-specific antibody  
present
2 (2) n – –
eosinophilia 1 (1) n – –
erythema 3 (1) Y – –
exposure during  
breast feeding
2 (2) n – –
exposure during  
pregnancy
5 (5) n – –
external auditory  
canal atresia
2 (2) n – –
Fatigue 4 (0) n 1 (1) n
Feeling hot 1 (0)
Fibrin D dimer  
increased
1 (1) n – –
headache 3 (1) Y – –
heart rate increased 1 (1) n – –
(Continued)
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dia”). Analyses of postmarketing data submitted to the US 
Food and Drug Administration ADR database showed ten 
cases of thromboembolic events from use of Cinryze®.28,29 
More than one half of the AEs found in EV were serious; 
however, this reporting pattern was not surprising, since 
physicians – from a clinical perspective – may find it more 
relevant to report serious reactions than nonserious reac-
tions.30 Due to the increasing number of patients diagnosed 
with HAE, more patients will get access to treatment with 
orphan drugs, despite the problems with patients’ access due 
to high prices and national restrictions in patients’ access,31 
and therefore, a larger number of ADR reports occurring 
from use of these medications is expected to be reported 
in the future.31–33
Reported aes by therapeutic groups and 
medications
The largest number of AEs was reported for the medication 
Cinryze®, which was expected since Cinryze® is frequently 
recommended and used in HAE patients.4–6 As expected, 
no ADR reports were found for Ruconest®, because this 
medicine is not prescribed very often for treatment of HAE. 
For  Cinryze®, a large number of AEs of the type “HAE” 
were reported, indicating that the medicine may increase the 
severity of the disease or that the patients/physicians have 
difficulties in distinguishing between disease symptoms and 
possible AEs from medication use. The use of orphan drugs 
in treatment of HAE is considered being low due to the small 
disease prevalence in EU, the price of the treatments,28 and 
limited access to these treatments in some member states.31 
Therefore, we also expected a low number of ADR reports 
present in EV, and our assumption was confirmed. However, 
the many serious cases may also indicate that health care 
professionals and patients report only unknown and serious 
events, which is also mandatory for the health care profes-
sionals operating in the individual EU member states. How-
ever, it is also well-known that a high rate of underreporting 
is biasing the spontaneous reporting systems and probably 
a much higher number of AEs have occurred in real life.34 
Therefore, we encourage the health care professionals and 
consumers/patients to continue reporting of suspected AEs 
in order to increase knowledge about ADRs from use of 
orphan drugs.
study limitations
The strength of this study is that it comprised all AEs reported 
for HAE medications in Europe, which were forwarded to 
the EV database during a 7-year period, hence a limitation 
Table 5 (Continued)
Adverse drug 
reaction  
(alphabetical order)
Cinryze® 
Total (n) 
(serious)
AE listed  
in PI  
(yes/no)
Firazyr® 
Total (n) 
(serious)
AE listed 
in PI  
(yes/no)
hepatic enzyme  
increased
– – 1 (1) n
hepatitis 3 (3) n 4 (4) n
hernia – n 1 (1) n
hereditary  
angioedema
25 (3) n 1 (1) n
hyperhidrosis 1 (0) n – –
hypersensitivity 1 (1) n – –
hypertension – – 1 (1) n
incorrect drug  
administration
3 (1) – – –
injection site reaction 5 (1) Y 14 (2) Y
laryngeal edema 2 (1) n – –
leukocytosis 1 (1) n – –
loss of consciousness – – 2 (2) n
Malaise 3 (1) n 1 (1) n
Muscle spasms/ 
tightness
2 (0) n 1 (1) n
Myocardial infarction – – 3 (3) n
nausea 2 (2) Y – Y
Obstructive airways  
disorder
1 (1) n – –
edema peripheral – – 1 (1) n
Off-label use 1 (1) – – –
Pain – – 1 (1) n
Pain in extremity – – 1 (1) n
Paresthesia – – 1 (1) n
Phlebitis 1 (1) Y – –
Poor venous access 4 (0) – – –
Pruritus 2 (0) Y – –
Pulmonary embolism 1 (1) n – –
Pyrexia 2 (2) Y – Y
swelling 1 (1) n 1 (1) n
swollen tongue 1 (1)
systemic lupus  
erythematous
– – 1 (1) Y
Tachycardia 1 (1) n – –
Urticaria 1 (1) n – –
Vomiting 1 (1) Y – –
Weight increased 1 (0) n – –
Total 138 (80) – 49 (36) –
Abbreviations: ae, adverse event; Pi: product information.
were also reported, and these reactions were all listed in 
the product information. The findings are in line with the 
ADR patterns reported in another study monitoring the 
safety of use of C1-inbibitors in different clinical settings 
in the US and in Europe.25 Thromboembolic events due to 
administration of C1-inhibitors have been of concern and 
discussed in the literature.26,27 In this study, only few cases 
were reported for Cinryze® (“basilar artery thrombosis” 
“increased level of coagulation factors IX and VIII”, “deep 
vein thrombosis”, “pulmonary embolism”, and “tachycar-
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adverse events reported for cinryze® and Firazyr® in europe
to this study is that we do not know to which extent the 
causality of the reported AEs can be confirmed, and this has 
implications for the interpretation of the findings. The respec-
tive pharmaceutical companies make causality assessment 
of ADR cases as a part of their legal obligations to monitor 
the safety of their marketed drugs. In this study, we did not 
evaluate the validity of the ADR reports since we only had 
access to the data entered into the EV database and not 
the ADR original reports; however, we expect the data to be 
valid, as they were predominantly entered into EV by the 
regulatory agencies. Spontaneous reporting systems suffer 
from various barriers, such as incomplete recognition of AEs, 
administrative barriers to reporting, and low data quality, all 
of which may result in underreporting of important serious 
and rarely occurring AEs.
Hence, AEs that are classified as being nonserious or 
already known may be underreported; however, this study 
provides information on the reported AEs, which contributes 
to broadening the knowledge on medicine safety. Hence, it 
is not possible to generalize from data reported to the EV 
database to the other EU member states, as the prescribing 
practice and disease diagnostic procedures may be very 
different. Although ADR reporting is mandatory in the EU, 
it is unknown whether the analyzed ADR data represent all 
information available in each country, and therefore, the 
actual ADR prevalence could not be estimated. Spontane-
ous reports are an important source of information about 
new and previously unrecognized AEs, and the value of 
spontaneous reporting schemes lies in their ability to act 
as hypothesis-generating procedures.35 Therefore, EMA 
and the national regulatory agencies should continue to 
systematically survey and analyze AEs reported by health 
care professionals/consumers and patients in order to signal 
previously unknown and rarely occurring AEs presumably 
related to use of orphan drugs.
Conclusion
Only a few AEs from use of HAE medications were identified 
in the EV database, but a large majority of these were seri-
ous, including fatal cases. There is a need of more research 
into the prescribing of these medicines to patients with HAE, 
as well as tighter reporting of AEs for HAE medicines pre-
scribed for this population, particularly from use in children 
and adolescents.
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